DepressionPhase 4NCT00034801
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
A Phase 4 study testing olanzapine and ziprasidone in people with Depression and Schizophrenia, run by Eli Lilly and Company at 30 sites in United States.
Trial summary
This is a research study comparing the safety and efficacy of two active study medications Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Depression, Schizophrenia, Schizoaffective Disorder
- What is being tested?
- olanzapine and ziprasidone
- How many people
- 378 participants
- Where
- 30 sitesUnited States
- Study dates
- Sep 2001to Mar 2003
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Male or female subjects 18-60 years of age
- Female subjects of childbearing potential must be using a medically accepted means of contraception
- Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol
- Subjects must be considered reliable
Who cannot join
- Treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry
- Female subjects who are either pregnant or nursing
- Uncorrected hypothyroidism or hyperthyroidism
- Narrow-angle glaucoma
Trial locations and contacts
30 sites in 1 country.
30 sites in 1 country
United States30 sites
Study site
Anaheim, California
Study site
Augusta, Georgia
Study site
Austin, Texas
Study site
Buffalo, New York
Study site
Charlotte, North Carolina
Study site
Chula Vista, California
Study site
Clementon, New Jersey
Study site
Denver, Colorado
Study site
El Paso, Texas
Study site
Gaithersburg, Maryland
Study site
Houston, Texas
Study site
Lafayette, California
Study site
Lincoln, Nebraska
Study site
Little Rock, Arkansas
Study site
Long Beach, California
Study site
Mount Pleasant, Michigan
Study site
New Britain, Connecticut
Study site
New York, New York
Study site
Orange, California
Study site
Philadelphia, Pennsylvania
Study site
Poway, California
Study site
Prairie Village, Kansas
Study site
Rosemeade, California
Study site
Salt Lake City, Utah
Study site
San Diego, California
Study site
Sioux Falls, South Dakota
Study site
St Louis, Missouri
Study site
Staten Island, New York
Study site
Tuscaloosa, Alabama
Study site
Winter Park, Florida
About this study
Official title: A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression
This is a research study comparing the safety and efficacy of two active study medications
- Conditions
- Depression, Schizophrenia, Schizoaffective Disorder
- Being tested
- olanzapine, ziprasidone
- Keywords
- Depression, Comorbid Depression, Schizophrenia, Schizoaffective Disorder
- Medical subject headings
- Depression, Schizophrenia, Psychotic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
olanzapineDrug
ziprasidoneDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2002 (estimated)
- Study startSep 2001
- Study completionMar 2003
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DepressionStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 378 participants
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00034801
- Sponsor's protocol ID
- 5529
- Other IDs
- F1D-US-HGJU
- Status last verified
- Jul 2006
- First submitted
- 2 May 2002
- Last updated
- 19 Jul 2006
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Jul 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression
- ClinicalTrials.gov ID
- NCT00034801
- Acronym / sponsor ID
- 5529
- Conditions
- Depression, Schizophrenia, Schizoaffective Disorder
- Keywords
- Depression, Comorbid Depression, Schizophrenia, Schizoaffective Disorder
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 378 participants
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- Sep 2001
- Study completion
- Mar 2003
- First posted
- 3 May 2002 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a research study comparing the safety and efficacy of two active study medications
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Male or female subjects 18-60 years of age
- Female subjects of childbearing potential must be using a medically accepted means of contraception
- Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol
- Subjects must be considered reliable
Key exclusion criteria (4 listed)
- Treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry
- Female subjects who are either pregnant or nursing
- Uncorrected hypothyroidism or hyperthyroidism
- Narrow-angle glaucoma
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| olanzapine | Drug | – |
| ziprasidone | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jul 2006.
Related trials for Depression
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Recruiting
Cultural Adaptation of an Online Parenting Intervention to Reduce the Risk of Depression and Anxiety in Adolescents
Risk of Depression and Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
30 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing olanzapine and ziprasidone in people with Depression and Schizophrenia, run by Eli Lilly and Company at 30 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jul 2006. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 30 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2006.